Tiagabine (Epilepsy = All indications) - Medication and Pregnancy KB

Tiagabine (Epilepsy = All indications)

Exposed non-exposed, cohort studies

Study	Country Study period Study design	Data source	Exposure definition	Non-exposure definition	Exposition period	Sample size (exposed/unexposed) Or (case / control)	Remarks	Risk of bias
Vajda (Tiagabine) (Controls exposed to Lamotrigine, sick) 2019	Australia 1999 - 2018 prospective cohort	The Australian Register of Antiepileptic Drugs in Pregnancy.	Offsprings born from women nearly always with epilepsy exposed to tiagabine in monotherapy in at least the first trimester of pregnancy. (This is a subgroup of exposure among the whole exposed group considered in the study).	exposed to other treatment, sick Offsprings born from women nearly always with epilepsy exposed to lamotrigine in monotherapy in at least the first trimester of pregnancy.	at least 1st trimester	1 / 406	Women with epilepsy accounted for 98.3%. Completely overlap Vajda 2014. Study design partly completed with Vajda 2013.
	Australia 1999 - 2018 prospective cohort		Details are obtained by four in-depth telephone interviews with the women. Details provided by the participants are confirmed, as far as possible, by the treating medical practitioners and through hospital records.		at least 1st trimester	1 / 406
Vajda (Tiagabine) (Controls unexposed, sick) 2019	Australia 1999 - 2018 prospective cohort	The Australian Register of Antiepileptic Drugs in Pregnancy.	Offsprings born from women nearly always with epilepsy exposed to tiagabine in monotherapy in at least the first trimester of pregnancy. (This is a subgroup of exposure among the whole exposed group considered in the study).	unexposed, sick Offsprings born from women nearly always with epilepsy not treated with antiepileptic drugs in at least the first half of pregnancy.	at least 1st trimester	1 / 176	Women with epilepsy accounted for 98.3%. Completely overlap Vajda 2014. Study design partly completed with Vajda 2013.
Vajda (Tiagabine) (Controls unexposed, sick) 2019	Australia 1999 - 2018 prospective cohort		Details are obtained by four in-depth telephone interviews with the women. Details provided by the participants are confirmed, as far as possible, by the treating medical practitioners and through hospital records.		at least 1st trimester	1 / 176

Case-control studies

Study	Country Study period Study design	Data source	Case	Control	Exposition	Exposition period	Sample size (exposed/unexposed) Or (case / control)	Remarks	Risk of bias

Risk of bias: : NA; : low; : moderate; : serious; : critical; : unclear;

Empty. There are no case-control studies available for this drug.

master protocol